4.8 Review

Role of viral respiratory infections in asthma and asthma exacerbations

期刊

LANCET
卷 376, 期 9743, 页码 826-834

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(10)61380-3

关键词

-

资金

  1. Novartis
  2. AstraZeneca
  3. GlaxoSmithKline
  4. MedImmune
  5. Ception
  6. MAP
  7. Gray Consulting
  8. Smith Research
  9. Quintiles
  10. Scienomics
  11. Genentech
  12. Pharmaxis
  13. Merck Inc
  14. NIAID/NIH [HHSN272200900052C, R01 HL097134]
  15. NIH [R01 HL097134, P01 HL070831, U10 HL064305, U10 HL074212, U10 HL098090, U19 AI070503]

向作者/读者索取更多资源

Viral respiratory tract infections are common and usually selflimited illnesses. For patients at risk of asthma, or with existing asthma, viral respiratory tract infections can have a profound effect on the expression of disease or loss of control. New evidence has shown that wheezing episodes early in life due to human rhinoviruses are a major risk factor for the later diagnosis of asthma at age 6 years. For those with existing asthma, exacerbations are a major cause of morbidity, can need acute care, and can, albeit rarely, result in death. Viral respiratory tract infections, predominantly those caused by human rhinoviruses, are associated with asthma exacerbations. There is also evidence that deficiencies in antiviral activity and the integrity of the airway epithelial barrier could make individuals with asthma more likely to have severe viral respiratory infections of the lower airway, and thus increase the risk of exacerbation. In view of the effect of respiratory viruses on many aspects of asthma, efforts to understand the mechanisms and risk factors by which these airway infections cause changes in airway pathophysiology are a first step towards improved treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据